Trials / Completed
CompletedNCT01299636
Study of PM060184 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- PharmaMar · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the maximum tolerated dose and the recommended dose and to evaluate the safety and tolerability of PM060184.
Detailed description
This trial intends to determine the maximum tolerated dose and the recommended dose, to evaluate the safety and tolerability, to determine the pharmacokinetics and to evaluate the antitumor activity of PM060184 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM060184 | PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2011-02-18
- Last updated
- 2015-11-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01299636. Inclusion in this directory is not an endorsement.